146 related articles for article (PubMed ID: 29749571)
1. Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
Enooku K; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Tsutsumi T; Nakagomi R; Minami T; Sato M; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Fukayama M; Koike K
J Gastroenterol; 2018 Dec; 53(12):1261-1275. PubMed ID: 29749571
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.
Birkenfeld AL; Shulman GI
Hepatology; 2014 Feb; 59(2):713-23. PubMed ID: 23929732
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Protects Cardiac Function and Energy Metabolism in Dilated Cardiomyopathy Induced by Loss of Cardiac IRS1 and IRS2.
Yan H; Yang W; Zhou F; Pan Q; Allred K; Allred C; Sun Y; Threadgill D; Dostal D; Tong C; Guo S
Circ Heart Fail; 2022 Jun; 15(6):e008758. PubMed ID: 35579013
[TBL] [Abstract][Full Text] [Related]
4. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
5. Advancing the global public health agenda for NAFLD: a consensus statement.
Lazarus JV; Mark HE; Anstee QM; Arab JP; Batterham RL; Castera L; Cortez-Pinto H; Crespo J; Cusi K; Dirac MA; Francque S; George J; Hagström H; Huang TT; Ismail MH; Kautz A; Sarin SK; Loomba R; Miller V; Newsome PN; Ninburg M; Ocama P; Ratziu V; Rinella M; Romero D; Romero-Gómez M; Schattenberg JM; Tsochatzis EA; Valenti L; Wong VW; Yilmaz Y; Younossi ZM; Zelber-Sagi S;
Nat Rev Gastroenterol Hepatol; 2022 Jan; 19(1):60-78. PubMed ID: 34707258
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
[TBL] [Abstract][Full Text] [Related]
7. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target.
Smati S; Polizzi A; Fougerat A; Ellero-Simatos S; Blum Y; Lippi Y; Régnier M; Laroyenne A; Huillet M; Arif M; Zhang C; Lasserre F; Marrot A; Al Saati T; Wan J; Sommer C; Naylies C; Batut A; Lukowicz C; Fougeray T; Tramunt B; Dubot P; Smith L; Bertrand-Michel J; Hennuyer N; Pradere JP; Staels B; Burcelin R; Lenfant F; Arnal JF; Levade T; Gamet-Payrastre L; Lagarrigue S; Loiseau N; Lotersztajn S; Postic C; Wahli W; Bureau C; Guillaume M; Mardinoglu A; Montagner A; Gourdy P; Guillou H
Gut; 2022 Apr; 71(4):807-821. PubMed ID: 33903148
[TBL] [Abstract][Full Text] [Related]
8. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
9. Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease.
Sarkar S; Saha P; Seth RK; Mondal A; Bose D; Kimono D; Albadrani M; Mukherjee A; Porter DE; Scott GI; Xiao S; Brooks B; Ferry J; Nagarkatti M; Nagarkatti P; Chatterjee S
Comp Biochem Physiol C Toxicol Pharmacol; 2020 Dec; 238():108854. PubMed ID: 32781293
[TBL] [Abstract][Full Text] [Related]
10. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank.
Jiang G; Luk AO; Tam CHT; Lau ES; Ozaki R; Chow EYK; Kong APS; Lim CKP; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JYY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung SKS; Cheng YL; Chow CC; Pearson ER; So WY; Chan JCN; Ma RCW; ;
PLoS Med; 2020 Jul; 17(7):e1003209. PubMed ID: 32722720
[TBL] [Abstract][Full Text] [Related]
11. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
Fan R; Papatheodoridis G; Sun J; Innes H; Toyoda H; Xie Q; Mo S; Sypsa V; Guha IN; Kumada T; Niu J; Dalekos G; Yasuda S; Barnes E; Lian J; Suri V; Idilman R; Barclay ST; Dou X; Berg T; Hayes PC; Flaherty JF; Zhou Y; Zhang Z; Buti M; Hutchinson SJ; Guo Y; Calleja JL; Lin L; Zhao L; Chen Y; Janssen HLA; Zhu C; Shi L; Tang X; Gaggar A; Wei L; Jia J; Irving WL; Johnson PJ; Lampertico P; Hou J
J Hepatol; 2020 Dec; 73(6):1368-1378. PubMed ID: 32707225
[TBL] [Abstract][Full Text] [Related]
12. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.
Bazerbachi F; Vargas EJ; Rizk M; Maselli DB; Mounajjed T; Venkatesh SK; Watt KD; Port JD; Basu R; Acosta A; Hanouneh I; Gara N; Shah M; Mundi M; Clark M; Grothe K; Storm AC; Levy MJ; Abu Dayyeh BK
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):146-154.e4. PubMed ID: 32360804
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
Kim SR; Lee SG; Kim SH; Kim JH; Choi E; Cho W; Rim JH; Hwang I; Lee CJ; Lee M; Oh CM; Jeon JY; Gee HY; Kim JH; Lee BW; Kang ES; Cha BS; Lee MS; Yu JW; Cho JW; Kim JS; Lee YH
Nat Commun; 2020 May; 11(1):2127. PubMed ID: 32358544
[TBL] [Abstract][Full Text] [Related]
14. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
15. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
Targher G; Byrne CD; Tilg H
Gut; 2020 Sep; 69(9):1691-1705. PubMed ID: 32321858
[TBL] [Abstract][Full Text] [Related]
16. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological Features of NAFLD From 1999 to 2018 in China.
Zhou J; Zhou F; Wang W; Zhang XJ; Ji YX; Zhang P; She ZG; Zhu L; Cai J; Li H
Hepatology; 2020 May; 71(5):1851-1864. PubMed ID: 32012320
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
19. Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study.
Niriella MA; Kasturiratna A; Beddage T; Ediriweera DS; De Silva ST; Perera KR; Subasinghe CE; Kodisinghe SK; Piyaratna TC; Rishikesawan V; Dassanayaka AS; De Silva AP; Pathmeswaran A; Wickramasinghe AR; Kato N; Janaka de Silva H
PLoS One; 2019; 14(10):e0224474. PubMed ID: 31661524
[TBL] [Abstract][Full Text] [Related]
20. HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype.
Malhotra R; Mauer AC; Lino Cardenas CL; Guo X; Yao J; Zhang X; Wunderer F; Smith AV; Wong Q; Pechlivanis S; Hwang SJ; Wang J; Lu L; Nicholson CJ; Shelton G; Buswell MD; Barnes HJ; Sigurslid HH; Slocum C; Rourke CO; Rhee DK; Bagchi A; Nigwekar SU; Buys ES; Campbell CY; Harris T; Budoff M; Criqui MH; Rotter JI; Johnson AD; Song C; Franceschini N; Debette S; Hoffmann U; Kälsch H; Nöthen MM; Sigurdsson S; Freedman BI; Bowden DW; Jöckel KH; Moebus S; Erbel R; Feitosa MF; Gudnason V; Thanassoulis G; Zapol WM; Lindsay ME; Bloch DB; Post WS; O'Donnell CJ
Nat Genet; 2019 Nov; 51(11):1580-1587. PubMed ID: 31659325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
